subscribeSubscribe
Novartis` Biologic Beovu ( Brolucizumab) Receives Approval in the U.S.

Novartis` Biologic Beovu ( Brolucizumab) Receives Approval in the U.S.
FDA
19 Dec 2022
Share Share
Novartis Korea`s AMD treatment Beovu wins expanded indication

Novartis Korea`s AMD treatment Beovu wins expanded indication
Lee Han-soo KOREABIOMED
17 Aug 2022
Share Share
Novartis Pharms` Biologic Beovu (brolucizumab-dbll) Receives Approval in U.S.

Novartis Pharms` Biologic Beovu (brolucizumab-dbll) Receives Approval in U.S.
FDA
09 Mar 2022
Share Share
Novartis Pharms` Biologic Beovu (Brolucizumab) Receives Approval in the U.S.

Novartis Pharms` Biologic Beovu (Brolucizumab) Receives Approval in the U.S.
FDA
18 Feb 2022
Share Share
Health Canada Issues Recall of Novartis Pharmaceuticals Canada`s BEOVU (brolucizumab)eutica

Health Canada Issues Recall of Novartis Pharmaceuticals Canada`s BEOVU (brolucizumab)eutica
HEALTH CANADA
05 Feb 2022
Share Share
Novartis reports positive data from diabetic macular oedema trial of Beovu

Novartis reports positive data from diabetic macular oedema trial of Beovu
CLINICALTRIALSARENA
10 Dec 2021
Share Share
Beovu shows positive results in two-year Phase III trial

Beovu shows positive results in two-year Phase III trial
Anna Begley EUROPEANPHARMACEUTICALREVIEW
10 Dec 2021
Share Share
Novartis announces positive results from Phase III trial of Beovu

Novartis announces positive results from Phase III trial of Beovu
PHARMAFILE
09 Dec 2021
Share Share
US FDA & EMA accepts Novartis’ sBLA for Beovu to treat diabetic macular edema

US FDA & EMA accepts Novartis’ sBLA for Beovu to treat diabetic macular edema
PHARMABIZ
14 Oct 2021
Share Share
Novartis announces positive phase III results of Beovu in diabetic macular edema

Novartis announces positive phase III results of Beovu in diabetic macular edema
PHARMABIZ
18 Aug 2021
Share Share